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Abstract: To investigate intraocular pressure (IOP) related patterns
before and after selective laser trabeculoplasty (SLT) for normal tension
glaucoma (NTG).
In this prospective cohort study, 18 NTG patients underwent SLT.
Success was defined as IOP reduction20% by Goldmann applanation
tonometry. 24-hour IOP-related pattern recording with a contact lens
sensor (CLS) (SENSIMED Triggerfish1, Sensimed, Switzerland)
was done before (baseline) and 1 month after SLT. A cosine function
was fitted to the mean CLS patterns for each individual in the SLT
success and non-success groups and the amplitude before and after
SLT was calculated. Diurnal, nocturnal, and 24-hour CLS pattern local
variability was determined for pre- and post-SLT sessions. Cosine
amplitude and variability were compared before and after SLT by
group using paired t-tests, with a¼ 0.05.
Patients (11 women, 7 men) had a mean age of 65.1 13.7 years.
Mean IOP was 15.3 2.2mmHg at baseline and was reduced by 17.0%
to 12.7 1.8mm Hg 1 month after SLT (P¼ 0.001). SLT was success-
ful in 8 patients (44%). The amplitude of the fitted cosine was reduced by
24.6% in the success group, but displayed an amplitude increase of 19.2%
post-SLT in the non-success group. Higher diurnal local variability of the
CLS pattern was observed after SLT in non-success subjects (P¼ 0.002),
while nocturnal variability showed no significant change. The increase in
diurnal variability in the non-success group led to an increase in 24-hour
variability in this group (P¼ 0.001). No change in local variability
(diurnal, nocturnal, and 24-hour) was seen in the success group.
The IOP-related pattern cosinor amplitude was reduced in NTG
patients with a successful SLT treatment whereas the non-success group
exhibited an increase of cosine amplitude. Higher diurnal and 24-hour
CLS pattern variability was observed in non-success patients 1 month
post-SLT.
(Medicine 93(27):e238)
Abbreviations: CLS = contact lens sensor, ET-1 = endothelin-1,n C.H. Chan, FRCSEd, and Jimmy S.M. Lai, MDINTRODUCTION
I ntraocular pressure (IOP) is still one of the most importantmodifiable risk factors for glaucoma progression,1–3 even in
glaucomas where the pressure is normal or low. A single IOP
measurement in the clinic is not an accurate depiction of the
pressure profile of glaucoma patients, as it does not account for
the influence of circadian rhythm and nocturnal posturing on
IOP.4,5 Various studies have documented IOP fluctuations
throughout the day and night using intermittent IOP measure-
ments taken a few hours apart6–10 but it is still uncertain
whether it is the frequency of IOP peaks or the range of IOP
fluctuation that leads to glaucoma progression.
Selective laser trabeculoplasty (SLT) is a non-invasive,
repeatable, and effective modality of IOP reduction for open
angle glaucoma.11–14 It has a similar efficacy to anti-glaucoma
eye drops and the former argon laser trabeculoplasty15 and a
recent study has affirmed SLT’s efficacy in normal tension
glaucoma (NTG), reducing the IOP by an additional 20% while
using 27% less medication at 6 months compared with pre-
treatment levels.16
In terms of IOP fluctuation, Kothy et al17 reported reduced
IOP fluctuation over a 24-hour period after SLT and Nagar
et al18 found that SLT’s ability to reduced diurnal IOP variation
was inferior to latanoprost. Prasad et al19 showed that there was
less inter-visit IOP fluctuation after 3608 SLT treatment com-
pared to 1808 SLT treatment. The majority of studies investi-
gating the effects of IOP reduction after SLT only measured IOP
over a few sampling periods or during clinical visits.
The SENSIMED Triggerfish1 (Sensimed AG, Lausanne,
Switzerland) is based on a wireless silicon contact lens sensor
(CLS).20 The device allows for the recording of the IOP related
pattern over a 24-hour period with minimal disturbance to
one’s daily routines and sleep cycle. The CLS records IOP-
related changes through the detection of biodimensional
changes in the corneoscleral area, for 30 seconds every 5min-
utes over 24 hours. Each recording ‘‘burst’’ represents 300 data
points, of which the median is plotted as a single graph of the
24-hour IOP-related profile. TheCLS output is in units ofmilli-
volts equivalent (mVeq). The device was CE-marked and
approved for clinical use in 2009. It has been shown to be
safe andwell tolerated during 24-hour recording of IOP-related
patterns in healthy subjects, glaucoma suspects, and glaucoma
patients.21,22
The purpose of the study was to analyze the IOP-related
fluctuations using the CLS before and after adjuvant SLT in
subjects with NTG who were treated with topical anti-glaucoma
medications.
PATIENTS AND METHODS
red to the tenets of the Declaration
patient consent and approval by the
Board were obtained prior to study
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2commencement. This study was supported by the provision of
SENSIMED Triggerfish1 CLS and other device supporting
items by Sensimed. There was no financial funding and the
authors have no proprietary interests.
This was a prospective cohort study from July 2012 to
June 2013, conducted at a Queen Mary Hospital, a university
hospital in Hong Kong Special Administrative Region, China.
The study recruited consenting adults (age> 18 years old) with
unilateral or bilateral NTG who were currently on topical anti-
glaucoma medications. NTG was defined by open angle on
gonioscopy, progressive thinning of the retinal nerve fiber layer
(RFNL) on the Spectralis1 (Heidelberg Engineering GmbH,
Heidelberg, Germany) Optical Coherence Tomography, and an
IOP< 21mm Hg during office hours. Subjects were excluded
for those with previous glaucoma surgery or laser, active or
previous corneal diseases, as well as subjects with only one
functional eye.
One week prior to SLT, subjects wore the CLS for
24 hours. The CLS was placed on the subject’s eye by a
single ophthalmologist in the clinic after a slit lamp exam-
ination and keratometry by the IOL Master 500 (Carl Zeiss,
Oberkochen, Germany) to determine the corneal curvature for
selection of the appropriate CLS base curve. For those with
unilateral disease, the CLS was placed on the eye with NTG.
For those with bilateral disease, a random eye assignment
from card shuffling was used to determine the eye for CLS
placement while SLT was scheduled for both eyes in subjects
with bilateral NTG. The subject then returned home with
lubricating eye drops and carried on their routine activities
(both indoor and outdoor), apart from showering or swim-
ming (as the device cannot be in contact with water). Subjects
continued the same regimen of anti-glaucoma eye drops and
slept in their habitual position at night. Each subject carried a
logbook to record sleeping and medication instillation times
during the 24-hour period. After 24 hours, the subject returned
to the clinic to have the contact lens removed followed by a
slit lamp examination. The data recorded by the CLS was
uploaded into a computer database. Goldmann applanation
tonometry (GAT) was performed before and after each CLS
wear by a single observer.
All patients then received a single SLT treatment by a
single surgeon (JWYL) in the same eye that wore the CLS. AQ-
switched Nd:YAG laser (Ellex SoloTM, Ellex Medical Pty. Ltd.,
Adelaide, SA, Australia) was used, with an initial energy of
0.8mJ and titrated until bubble formation was just invisible.
Treatment was delivered in a single burst mode until 3608 of the
trabecular meshwork was treated.
At 1-month post-SLT, patients wore the CLS in the same
eye that received the first CLS recording. As before, the CLS
was removed 24 hours later.
All topical anti-glaucoma medications remained
unchanged until after the second (post-SLT) CLS wearing.
Anti-glaucoma medications were then titrated (decreased or
increased) after 1 month of SLT based on an individual target
IOP, calculated as a 30% reduction from their documented
presenting IOP (prior to starting anti-glaucoma medication)
as per the Collaborative Normal Tension Glaucoma Study.23
Patients were followed-up every 3 months thereafter. The
order of resuming anti-glaucoma medication included
first the use of alpha adrenergic agonists or prostaglandin
analogs followed by topical carbonic anhydrase inhibitors or
Lee et alb-blockers. When multiple medications were required, fixed
combination medications were given to simplify the drug
regime.
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Local variability: CLS IOP-related variability was measured
over 24 hours, diurnally, and nocturnally. This was a
measure of local variability of the raw CLS data from the
smoothed function obtained using a locally weighted
polynomial regression method (shown below).24 This
parameter reflects the error of the smoothed function, or
the amount of information that is ‘‘missed’’ by the smoothed
values.
CLS variability y ¼ 1
T  1
XN
i¼1
jTFo  TFpj
where T is the number of CLS measurements over the
recording period, TFO is the observed CLS signal, and TFP
is the predicted CLS signal based on the smoothing
function selected.
Global variability: Cosinor modeling of 24-hour CLS
patterns was performed using the below formula. The
cosinor model represents the actual amplitude of IOP-
related fluctuation over a 24-hour period and is most
representative of IOP-related changes
yðtÞ ¼ b0þ b1 cos 2p
24
t
 
þ b2 sin 2p
24
t
 where y is the observed signal in mVeq, t is the time, and b0,
b1, and b2 are the regression coefficients, estimated from
the data.
3 SLT success rates: GAT IOP reductions20% from the pre-
SLT levels while on the same anti-glaucoma regimen at
1-month post-SLT.
e Secondary Outcomes IncludedTh1 CLS increase and decrease rates (change in CLS units/
change in time): maximum, minimum, median, and mean.
Number of peaks: over 24 hours, <30minutes, >90mVeq.2
3 Sleep-to-wake and wake-to-sleep slopes. The calculation of
sleep-to-wake and wake-to-sleep slopes has been described
previously by Mansouri et al22
4 The reduction in IOP after SLTwas calculated based on the
GAT IOP measured at baseline, 1 month, and 3 months after
SLT. These GAT IOP readings were taken at approximately
3 PM each visit and taken before the CLS wear at the baseline
and 1-month post-SLT visits.
Statistics
All statistical calculations were done using SPSS version
18.0 (SPSS, Inc., Chicago, IL). The differences between the
measured parameters detailed above, were compared before and
after SLT using the paired t-test or Wilcoxon matched pairs
test depending on the normality of the variable distribution.
Statistical significance was taken as P 0.05 and all means
were expressed as mean standard deviation.
RESULTS
In 18 subjects that were enrolled in the study, there were
ales and 11 females. The mean age was 65.1 13.7 years.
subjects were ethnic Chinese with pigmented trabecular
shwork and NTG. The mean of the average RNFL thickness
# 2014 Lippincott Williams & Wilkins
Blue tracing = CLS pattern at 1 week before SLT
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Medicine  Volume 93, Number 27, December 2014 24-Hour IOP After SLT for NTGwas 72.9 9.5micrometers (mm). One subject did not accu-
rately record his sleeping and waking times, thus, to ensure the
accuracy of the data, this subject was excluded from analyses
that required the input of sleeping and waking times.
The baseline (pre-SLT) GAT IOP was 15.3 2.2mm Hg
while on 1.7 0.7 types of anti-glaucoma eye drops. All sub-
jects received a single session of SLT with a mean of
198.2 22.9 shots with a mean energy of 0.9 0.09mJ. There
were no complications from SLT.
The distributions of anti-glaucoma eye drops were:
b-blockers (32.0%), prostaglandins (20.0%), fixed combination
prostaglandin-b-blocker (20.0%), brimonidine (12.0%), and
topical carbonic anhydrase inhibitors (8.0%).
The IOP-related pattern of the 18 subjects was unique in
terms of their peaks and slopes. This personal IOP-related
pattern remains similar in shape before and after SLT and it
is only the CLS pattern amplitude and steepness of slopes that
change. Figure 1 shows the 24-hour IOP-related pattern before
and after SLT.
At 1 month after SLT, the mean GAT IOPmeasured before
the CLS wear was 12.7 1.8mm Hg while on the same anti-
glaucoma medication regimen as before laser, representing a
17.0% reduction in IOP after SLT (P¼ 0.001). At 3 months
post-SLT, the mean GAT IOP was 11.4 1.7mm Hg while on
1.4 1.2 types of anti-glaucoma eye drops, representing a
25.5% (P¼ 0.0007) IOP reduction in addition to a 17.6%
medication reduction compared to pre-SLT levels. Eight out
of 18 (44.4%) subjects fulfilled the criteria of a successful
Yellow tracing = CLS pattern at 1 month after SLT
FIGURE 1. Twenty-four-hour IOP-related pattern before and afterSLT outcome.
The measured pre- and post-SLT parameters are summar-
ized in Table 1 to 4. From initially similar levels, the mean
TABLE 1. Mean Global Variability Using the Cosinor Model Befo
SLT Success
Pre-SLT
(n¼ 8)
Post-SLT
(n¼ 8) % Change
Pre-SLT
(n¼ 10)
Cosinor amplitude
(mVeq)
79.0 59.6 24.6 75.9
# 2014 Lippincott Williams & Wilkinsacrophase amplitude of the fitted cosinor function (global
variability) was reduced after SLT by 24.6% in the success
subjects (Table 1). In subjects for whom the SLT was unsuc-
cessful, the global variability increased by 19.2% post-SLT,
indicating greater 24-hour IOP-related fluctuation after SLT
(Figure 2A and B).
For the local variability in the non-success group, the 24-
hour variability increased by 21.9% (P¼ 0.001), driven by the
magnified 34.1% increase in diurnal variability (P¼ 0.002),
while the nocturnal variability remained unchanged (P¼ 0.8).
For the success group, there was no significant difference in local
variability over 24-hours, nocturnal, or diurnal (P> 0.7). For the
mean sleep-to-wake slope, the slope was negative in both groups
signifying a decrease in CLS output with waking. In the non-
success group, the sleep-to-wake slope was flatter after SLT
(P¼ 0.04). No significant changes in variability or sleep-to-wake
slopewere observed in theSLT success group (P¼ 0.2) (Table 2).
For the overall study population, local diurnal (22.5%,
P¼ 0.01) and 24-hour (12.1%, P¼ 0.04) variability was higher
post-SLT, mainly attributed by the increases in the non-success
group detailed above (Table 2). The number of peaks
>90mVeq increased (P¼ 0.04) and the number of diurnal
troughs decreased (P¼ 0.01) after SLT, independent of SLT
success (Table 3). The mean number of peaks over the 24-hour
period as well as the number of peaks <30minutes were not
affected by SLT (Table 3). There was no significant difference
in the rates of CLS increase or decrease before or after SLT
(Table 4). Area under the nocturnal part of the CLS curve was
T.also not significantly different after SLT as compared to before
(not shown). Table 5 compared the differences in pre- and post-
SLT parameters between the success versus non-success group.
re and After SLT
Non-Success Overall
Post-SLT
(n¼ 10) % Change
Pre-SLT
(n¼ 18)
Post-SLT
(n¼ 18) % Change
90.5 19.2 76.0 76.6 0.8
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Lee et al Medicine  Volume 93, Number 27, December 2014DISCUSSION
Previous studies have reported the significance of IOP
fluctuation on glaucoma progression.25,26 While there are stu-
dies that have reported otherwise,27,28 much of the existing
literature only documented inter-visit IOP variability or daytime
IOP variability over a limited number of IOP measurements. To
the best of our knowledge, this is one of the first studies
FIGURE 2. (A) Twenty-four-hour IOP-related pattern (global) va
(global) variability in non-success group.investigating the IOP-related fluctuation after SLT for medi-
cally treated NTG subjects by the use of a 24-hour continuous
IOP related pattern recording device.
4 | www.md-journal.comSLT was effective in lowering the mean GAT IOP by
17.0% at 1 month and 25.5% at 3 months, in addition to a 17.6%
reduction in anti-glaucoma medication compared to pre-SLT
baseline levels. Using the CLS for 24-hour continuous IOP-
related pattern recording before and 1 month after SLT, we
observed a reduction of mean global variability using the
cosinor model in the SLT success group, which was anticipated
ility in success group. (B) Twenty-four-hour IOP-related patternbased on previous reports in the literature.17–19,29 The CLS has
previously been reported to be an accurate and reproducible
method to model IOP rhythm.30 For local variability, we noted a
# 2014 Lippincott Williams & Wilkins
TABLE 2. Mean Local Variability and Sleep-to-Wake Slope Before and After SLT
SLT Success SLT Non-Success Overall
Pre-SLT
(n¼ 8)
Post-SLT
(n¼ 8) P-Value
Pre-SLT
(n¼ 10)
Post-SLT
(n¼ 10) P-Value
Pre-SLT
(n¼ 18)
Post-SLT
(n¼ 18) P-Value
24-Hour variability
(mVeq)
12.5 4.2 12.6 3.6 1.0 13.7 3.0 16.7 3.9 0.001 13.2 3.2 14.8 4.2 0.04
Nocturnal variability
(mVeq)
10.6 3.3 10.5 2.0 0.9 14.0 3.8 13.6 4.3 0.8 12.6 3.9 12.3 3.8 0.7
Diurnal variabilityy
(mVeq)
13.7 5.5 14.6 5.6 0.7 13.8 3.3 18.5 4.4 0.002 13.8 4.2 16.9 5.2 0.01
Sleep-to-wake slopey
(mVeq)
33.3 47.3 6.8 33.2 0.2 48.9 49.3 13.5 54.0 0.04 42.5 47.6 10.8 45.4 0.02
p/w
Medicine  Volume 93, Number 27, December 2014 24-Hour IOP After SLT for NTGsignificant 34.1% increase in diurnal variability and a 21.9%
increase in the 24-hour variability after non-successful SLT.
This increase in diurnal variability caused significant increase in
the diurnal and 24-hour variability in the overall study popu-
lation (22.5% and 12.1%, respectively) while in the SLT
success group, there was no significant increase in diurnal,
nocturnal, or 24-hour local variability. It should be noted that
local variability in this study was defined as the variation of raw
CLS data around the smoothed curve, hence it was a measure of
the local variability of the CLS as opposed to the global
variability that implemented a cosinor model where the ampli-
tude was representative of IOP-related fluctuation over
24 hours. There was also evidence of an overall greater number
of peaks >90mVeq after SLT. Previous studies in rats have
demonstrated that rapid IOP spikes can result in greater damage
to retinal ganglion cells than persistently elevated IOP levels
although the effect on humans is yet to be determined.31
Nagar et al18 previously reported a 41% reduction in IOP
fluctuation in 50% of subjects treated with SLT. However, their
study subjects consisted of subjects with primary open angle
glaucoma (POAG) or ocular hypertension with a pre-SLT IOP
of 26.0mm Hg and IOP was only measured during 4 time
intervals at 08:00, 11:00, 14:00, and 18:00 hours.18 In contrast,
our population consisted of only NTG subjects with a pre-SLT
IOP of 15.3 2.2mm Hg while on 1.7 0.7 types of anti-
glaucoma eye drops and our IOP-related pattern recording was
on a continuous basis for 24 hours. Thus, the timing and

Statistically significant.
yOnly 17 subjects included as 1 subject incorrectly recorded his sleefrequency of IOP measurement is important in accurately
assessing the effects of SLT on IOP control. Kothy et al17
reported in their POAG series that after SLT, 5 eyes had IOP
TABLE 3. Number of Peaks and Troughs Before and After SLT
Parameters Pre-SLT (n¼ 18)
Number of peaks over 24 hours 15.3 5.7
Number of peaks <30minutes 4.7 3.1
Number of peaks >90mVeq 1.7 1.1
Number of diurnal troughsy 9.9 2.4
Number of nocturnal troughsy 5.9 2.3

Statistically significant.
yOnly 17 subjects used as 1 subject incorrectly recorded his sleep/wake
# 2014 Lippincott Williams & Wilkinsreduction >20% during office hour (08:00–12:00 hours) but
none of the 26 eyes had a mean IOP reduction of 20% when
the assessment period was extended from 08:00 to 00:00 hours.
The influence of SLT on diurnal and nocturnal IOP fluctuation
is also diversified in the literature and probably related to
whether or not anti-glaucoma medications were used. Kothy
et al17 reported a significant reduction in diurnal IOP fluctuation
of 4.3 1.7 and 5.0 1.7mm Hg at 3 and 6 months after SLT,
respectively, in their POAG population after a 4-week washout
period prior to SLT. In contrast, Lee et al32 reported in their
medically treated POAG patients that after SLT, IOP range was
significantly reduced nocturnally but not diurnally. Both of
these studies however, only measured IOP at intervals rather
than continuously over 24 hours. Therefore, the influence of
SLT on IOP fluctuation cannot be fully evaluated using interval
or daytime IOP measurements alone.
In this study, SLT was offered as an adjuvant therapy for
NTG with the aim of further lowering IOP or to reduce the anti-
glaucoma medication requirement. The authors decided not to
washout anti-glaucoma medication prior to SLT in order to
simulate the realistic clinical scenario where adjuvant SLT is
offered to medically controlled NTG patients to reduce medi-
cation load or for those with poor adherence or intolerant to
topical anti-glaucoma medications. In addition, there is no
definite consensus from the literature on the negative influence
of topical prostaglandin analogs on SLT outcome. In a retro-
spective study by Scherer,33 a greater mean IOP reduction was
ake times.demonstrated following SLT in POAG subjects being treated
with topical prostaglandin analogs. Alvarado et al34 on the other
hand, showed that prostaglandin analogs might dampen the
Post-SLT (n¼ 18) P-Value
14.1 3.0 0.2
4.8 2.4 0.9
2.4 1.5 0.04
8.5 2.0 0.01
5.3 1.9 0.6
times.
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TABLE 4. CLS Pattern Increase and Decrease Rates Before and After SLT
Parameter Pre-SLT (n¼ 18) Post-SLT (n¼ 18) P-Value
Maximum increase rate 104.3 49.2 126.6 85.1 0.2
Maximum reduction rate 109.4 67.4 126.0 73.4 0.2
Median increase rate 41.7 15.9 38.8 19.4 0.48
Median reduction rate 34.7 13.2 41.5 16.1 0.19
Mean increase rate 45.1 15.3 45.3 21.2 1.0
Mean reduction rate 42.1 16.9 46.9 17.3 0.3
Lee et al Medicine  Volume 93, Number 27, December 2014IOP-lowering effects of SLT while Singh et al35 reported no
significant difference in SLT outcome with prostaglandin
analog use.
The findings of our study suggest that adjuvant and
successful SLT may offer an additional benefit reducing
24-hour IOP-related fluctuation for NTG patients who are
already on anti-glaucoma medication. The majority of our
patients (40%) was on a once nightly topical prostaglandin
analog or fixed combination prostaglandin-b-blocker and 32%
were on a topical b-blocker. SLT and prostaglandin analogs
have been postulated to share a common IOP-lowering pathway
by opening up the intercellular junction and increasing con-
ductivity at level of the Schlemm canal endothelial cells.34 We
postulate that after the prostaglandin analogs reach their
maximal IOP-lowering effect at 8 to 12 hours after instillation,36
this leads to the rebound in diurnal IOP fluctuation. For those
subjects who were responsive to SLT (the success group), their
diurnal variability was kept low by the continued effects of the
SLT, accounting for the significantly lower diurnal variability
as compared to the non-success group.
In all 18 subjects, both before and after SLT, the wake-to-
sleep slope was positive and the sleep-to-wake slope was
negative, signifying that the supine-posture induced IOP
increases are still preserved after adjuvant SLT. There was
no significant difference in the wake-to-sleep slope before and
after SLT (P¼ 0.9). However, the sleep-to-wake slope was
Minimum increase rate 5.3 3.4
Minimum reduction rate 3.7 3.0dampened by 3.9 times, following SLT (P¼ 0.02) signifying
a more gradual drop in IOP upon waking after SLT. It has been
demonstrated in animal models that SLT may increase the
TABLE 5. Comparison of Differences in Pre- and Post-SLT
Parameters Between the Success Versus Non-Success Group
Parameter P-Value
Maximum increase rate 0.656
Maximum reduction rate 0.789
Median increase rate 0.929
Mean increase rate 0.858
Mean reduction rate 1.000
Median reduction rate 1.000
Minimum increase rate 1.000
Minimum reduction rate 0.929
Number of peaks <30minutes 0.375
Number of peaks >90mVeq 1.000
Number of peaks over 24 hours 0.623
Sleep-to-wake slope 0.588
Wake-to-sleep slope 0.657
6 | www.md-journal.comexpression of aqueous endothelin-1 (ET-1) in the early post-
laser periods, which can reduce aqueous outflow, explaining the
slower drop in IOP upon waking.37 The magnitude and duration
of ET-1 influence following SLT has not been well established
in human subjects. However, we do not have an account for why
only the sleep-to-wake slope was affected as the daytime IOP
was reduced after SLT signifying an increase in aqueous
outflow overall.
Our study had its limitations. Firstly, the IOP related
fluctuation was monitored at 1-month post-SLT. Although it
has been established that the post-SLT IOP values as early as
2 weeks were predictive of future IOP control,38 future studies
monitoring 24-hour continuous IOP changes at a longer time
frame after SLT would provide more long-term results.39
Secondly, at present, the CLS can only measure IOP-related
fluctuations in mVeq. The GAT before CLS wear was used as a
reference baseline. There are no effective formulae to convert
these readings into the gold standard unit of IOP measurement
(mm Hg). Further developments in this area would popularize
the use of this device in clinical practice. Thirdly, due to the
high cost and single use nature of the CLS, the sample size was
relatively small due to the constraints of resources. Further
studies involving larger samples should be carried out to further
strength the preliminary conclusions drawn from this study.
Fourthly, the observations from our study are only applicable to
medically treated NTG patients and may not be generalizeable
to other glaucoma patients or to those without baseline anti-
glaucoma medication prior to SLT.
Nevertheless, this study has served to provide objective
evidence for the controversies around IOP fluctuations after
SLT by evaluating IOP related changes in a 24-hour, continuous
manner. It seems that SLT was able to produce a significant IOP
reduction measured at a single time point during the day,
accompanied by dampened amplitude of the nycthemeral
rhythm in patients for whom SLT was successful but an
increased in those where SLT was not successful. Our findings
confirm the relevance of continuous 24-hour IOP-related pat-
tern monitoring in the accurate evaluation of glaucoma treat-
ments. Further trials involving larger samples, different
glaucoma subtypes, and groups with and without baseline
anti-glaucoma medications would provide us with a clearer
understanding of the influence of SLT on IOP fluctuation.
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